Danaher Co. (NYSE:DHR) Holdings Lowered by SVB Wealth LLC

SVB Wealth LLC trimmed its stake in shares of Danaher Co. (NYSE:DHR) by 4.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,823 shares of the conglomerate’s stock after selling 2,261 shares during the quarter. SVB Wealth LLC’s holdings in Danaher were worth $12,698,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Cape Investment Advisory Inc. acquired a new position in shares of Danaher in the 4th quarter worth approximately $25,000. Tsfg LLC grew its stake in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the 2nd quarter worth approximately $25,000. nVerses Capital LLC acquired a new position in shares of Danaher in the 2nd quarter worth approximately $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in shares of Danaher in the 1st quarter worth approximately $30,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of Danaher stock traded up $1.49 on Friday, reaching $266.20. The stock had a trading volume of 3,324,729 shares, compared to its average volume of 2,790,567. The business’s 50-day moving average price is $261.30 and its two-hundred day moving average price is $255.73. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The stock has a market cap of $197.17 billion, a P/E ratio of 45.12, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the company earned $2.05 earnings per share. Danaher’s revenue for the quarter was down 2.9% on a year-over-year basis. On average, sell-side analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Linda Filler sold 3,928 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.50, for a total value of $1,097,876.00. Following the sale, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on DHR shares. Jefferies Financial Group started coverage on shares of Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price on the stock. Robert W. Baird lifted their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. TD Cowen lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Bank of America lifted their target price on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, Leerink Partners lifted their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.